{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:39:41Z","timestamp":1777052381062,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The authors declare that they have no conflict of interest"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00277-018-3379-5","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T18:58:41Z","timestamp":1532717921000},"page":"1817-1824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Brentuximab vedotin as salvage treatment in Hodgkin lymphoma na\u00efve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP)"],"prefix":"10.1007","volume":"97","author":[{"given":"Vincenzo","family":"Pavone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommasina","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizio","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Guarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Loseto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prete","family":"Eleonora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Cascavilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Potito","family":"Scalzulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Melpignano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Di Renzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Tarantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Capalbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,27]]},"reference":[{"key":"3379_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/annonc\/mdi119","volume":"16","author":"A Sureda","year":"2005","unstructured":"Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, Petit J, L\u00f3pez A, Lahuerta JJ, Carreras E, Garc\u00eda-Conde J, Garc\u00eda-Lara\u00f1a J, Cabrera R, Jarque I, Carrera D, Garc\u00eda-Ruiz JC, Pascual MJ, Rif\u00f3n J, Moraleda JM, P\u00e9rez-Equiza K, Alb\u00f3 C, D\u00edaz-Mediavilla J, Torres A, Torres P, Besalduch J, Mar\u00edn J, Mateos MV, Fern\u00e1ndez-Ra\u00f1ada JM, Sierra J, Conde E (2005) Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse. Ann Oncol 16:625\u2013633","journal-title":"Ann Oncol"},{"key":"3379_CR2","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","volume":"12","author":"NS Majhail","year":"2006","unstructured":"Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, Burns LJ (2006) Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant 12:1065\u20131072","journal-title":"Biol Blood Marrow Transplant"},{"key":"3379_CR3","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1093\/annonc\/mdt206","volume":"24","author":"C Mart\u00ednez","year":"2013","unstructured":"Mart\u00ednez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A, Sica S, Trneny M, Snowden JA, Kanfer E, Milpied N, Bosi A, Guidi S, de Souza CA, Willemze R, Arranz R, Jebavy L, Hellmann A, Sibon D, Oneto R, Luan JJ, Dreger P, Castagna L, Sureda A (2013) Identification of prognostic factors predicting outcome in Hodgkin\u2019s lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 24:2430\u20132434","journal-title":"Ann Oncol"},{"key":"3379_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","volume":"146","author":"AJ Moskowitz","year":"2009","unstructured":"Moskowitz AJ, Perales MA, Kewalramani T, Yahalom J, Castro-Malaspina H, Zhang Z, Vanak J, Zelenetz AD, Moskowitz CH (2009) Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 146:158\u2013163","journal-title":"Br J Haematol"},{"key":"3379_CR5","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.2001.19.5.1395","volume":"19","author":"A Sureda","year":"2001","unstructured":"Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garc\u00eda-Conde J, Jarque I, Caballero MD, Ferr\u00e0 C, L\u00f3pez A, Garc\u00eda-Lara\u00f1a J, Cabrera R, Carrera D, Ruiz-Romero MD, Le\u00f3n A, Rif\u00f3n J, D\u00edaz-Mediavilla J, Mataix R, Morey M, Moraleda JM, Alt\u00e9s A, L\u00f3pez-Guillermo A, de la Serna J, Fern\u00e1ndez-Ra\u00f1ada JM, Sierra J, Conde E (2001) Autologous stem-cell transplantation for Hodgkin\u2019s disease: results and prognostic factors in 494 patients from the Grupo Espa\u00f1ol de Linfomas\/Transplante Aut\u00f3logo de M\u00e9dula Osea Spanish cooperative group. J Clin Oncol 19:1395\u20131404","journal-title":"J Clin Oncol"},{"key":"3379_CR6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.1993.11.4.704","volume":"11","author":"M Crump","year":"1993","unstructured":"Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, Scott JG, McCrae J, Murray C, Pantalony D et al (1993) High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin\u2019s disease: importance of disease status at transplant. J Clin Oncol 11:704\u2013711","journal-title":"J Clin Oncol"},{"key":"3379_CR7","first-page":"13","volume":"16","author":"LJ Burns","year":"1995","unstructured":"Burns LJ, Daniels KA, McGlave PB, Miller WJ, Ramsay NK, Kersey JH, Weisdorf DJ (1995) Autologous stem cell transplantation for refractory and relapsed Hodgkin\u2019s disease: factors predictive of prolonged survival. Bone Marrow Transplant 16:13\u201318","journal-title":"Bone Marrow Transplant"},{"key":"3379_CR8","doi-asserted-by":"publisher","first-page":"10540","DOI":"10.1074\/jbc.M510026200","volume":"281","author":"MS Sutherland","year":"2006","unstructured":"Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law CL, Wahl AF (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 281:10540\u201311054","journal-title":"J Biol Chem"},{"key":"3379_CR9","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458\u20131465","journal-title":"Blood"},{"issue":"18","key":"3379_CR10","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30(18):2183\u20132189","journal-title":"J Clin Oncol"},{"issue":"12","key":"3379_CR11","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128(12):1562\u20131566","journal-title":"Blood"},{"issue":"26","key":"3379_CR12","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1182\/blood-2012-03-418673","volume":"119","author":"R Chen","year":"2012","unstructured":"Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, Forman SJ, Gopal AK (2012) Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 119(26):6379\u20136381","journal-title":"Blood"},{"issue":"5","key":"3379_CR13","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/imj.13415","volume":"47","author":"H Mediwake","year":"2017","unstructured":"Mediwake H, Morris K, Curley C, Butler J, Kennedy G (2017) Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed\/refractory CD30 positive lympho-proliferative disorders: a single centre experience. Intern Med J 47(5):574\u2013578","journal-title":"Intern Med J"},{"issue":"21","key":"3379_CR14","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P (2016) Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128(21):2489\u20132496 Review","journal-title":"Blood"},{"key":"3379_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"G Kaplan","year":"1958","unstructured":"Kaplan G, Meier P (1958) Non-parametric estimations from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"3379_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdi003","volume":"16","author":"A Josting","year":"2005","unstructured":"Josting A, Rudolph C, Mapara M, Glossmann JP, Sieniawski M, Sieber M, Kirchner HH, D\u00f6rken B, Hossfeld DK, Kisro J, Metzner B, Berdel WE, Diehl V, Engert A (2005) Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin lymphoma study group (GHSG). Ann Oncol 16(1):116\u2013123","journal-title":"Ann Oncol"},{"issue":"3","key":"3379_CR17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood.V97.3.616","volume":"97","author":"CH Moskowitz","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, Louie D, Gonzales M, Walits J, Coady-Lyons N, Qin J, Frank R, Bertino JR, Goy A, Noy A, O'Brien JP, Straus D, Portlock CS, Yahalom J (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97(3):616\u2013623","journal-title":"Blood"},{"issue":"2","key":"3379_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/cncr.21587","volume":"106","author":"J Kuruvilla","year":"2006","unstructured":"Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M (2006) Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106(2):353\u2013360","journal-title":"Cancer"},{"issue":"12","key":"3379_CR19","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","volume":"17","author":"CH Moskowitz","year":"1999","unstructured":"Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol 17(12):3776\u20133785","journal-title":"J Clin Oncol"},{"issue":"6","key":"3379_CR20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","volume":"18","author":"NL Bartlett","year":"2007","unstructured":"Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP (2007) Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804. Ann Oncol 18(6):1071\u20131079","journal-title":"Ann Oncol"},{"issue":"12","key":"3379_CR21","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","volume":"21","author":"R Chen","year":"2015","unstructured":"Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ (2015) Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 21(12):2136\u20132140","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"3379_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1634\/theoncologist.2015-0227","volume":"20","author":"PL Zinzani","year":"2015","unstructured":"Zinzani PL, Pellegrini C, Cantonetti M, Re A, Pinto A, Pavone V, Rigacci L, Celli M, Broccoli A, Argnani L, Pulsoni A et al (2015) Brentuximab vedotin in transplant-na\u00efve relapsed\/refractory Hodgkin lymphoma: experience in 30 patients. Oncologist 20(12):1413\u20131416","journal-title":"Oncologist"},{"issue":"7","key":"3379_CR23","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.bbmt.2016.03.028","volume":"22","author":"P Anderlini","year":"2016","unstructured":"Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE (2016) Gemcitabine, fludarabine, and melphalan for reduced-intensity conditioning and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 22(7):1333\u20131337","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"3379_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/bmt.2016.357","volume":"52","author":"L Hegerova","year":"2017","unstructured":"Hegerova L, Cao Q, Lazaryan A, McClune BL, Weisdorf DJ, Brunstein CG, Bachanova V (2017) Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. Bone Marrow Transplant 52(5):697\u2013703","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3379_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjh.15152","volume":"181","author":"A Bazarbachi","year":"2018","unstructured":"Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, Blaise D, Afanasyev B, Diez-Martin JL, Sierra J, Bloor A, Martinez C, Robinson S, Malladi R, El-Cheikh J, Corradini P, Montoto S, Dreger P, Sureda A (2018) Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Br J Haematol 181(1):86\u201396","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3379-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3379-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3379-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T23:07:30Z","timestamp":1564182450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3379-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,27]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["3379"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3379-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,27]]},"assertion":[{"value":"12 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}